M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
Unlike most ADHD medications on the market, this medication is a non-stimulant option.
- Unlike most ADHD medications on the market, this medication is a non-stimulant option.
- A second phase 4 clinical trial in preschool age children with ADHD is planned to commence in January 2024.
- A third phase 4 clinical trial is studying the impact of Qelbree® on co-morbid mood symptoms prevalent in patients with ADHD.
- The collaboration will provide prescribers with a new option to improve the ADHD treatment paradigm for millions of patients.